AVROBIO
One Kendall Square
Building 300, Suite 201
Cambridge
MA
02139
United States
Tel: 617.914.8420
Website: https://avrobio.com/
Email: info@AVROBIO.com
About AVROBIO
AVROBIO, Inc., a leader in lentiviral-based gene therapies, is a clinical-stage company developing disruptive therapies that have the potential to transform patients’ lives with a single dose. The Company is focused on the development of its gene therapy candidate, AVR RD 01, in Fabry disease, as well as additional gene therapy programs in other lysosomal storage disorders including Gaucher disease, cystinosis and Pompe disease. AVROBIO’s lentiviral platform has broad potential for other rare and non-rare genetic diseases.
We are headquartered in Cambridge, MA and have offices in Toronto, ON. Please visit our website www.avrobio.com for more information on who we are, what we care about and how we are bringing these therapies to our patients.
160 articles about AVROBIO
-
AVROBIO to Present at Three Upcoming Investor Conferences in March
2/25/2021
AVROBIO to Present at Three Upcoming Investor Conferences in March
-
Clinical Catch-Up: February 8-12
2/15/2021
It was a busy week for clinical trial announcements and news. Here’s a look. -
AVROBIO Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato® Gene Therapy Platform in Fabry Disease Phase 2 Trial
2/8/2021
AVROBIO Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato ® Gene Therapy Platform in Fabry Disease Phase 2 Trial Consistent with the 87% reduction in the first evaluable kidney biopsy, there is complete clearance of Gb3 inclusions in second evaluable kidney biopsy in Fabry disease Phase 2 trial
-
Shares of Avrobio were up nearly 20% in premarket trading after the company posted positive clinical data from its gene therapy trials in three different rare lysomal diseases, Fabry, Gaucher type 1 and cystinosis.
-
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 05, 2021
2/5/2021
AVROBIO, Inc., a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, announced that the company has granted a non-statutory stock option for the purchase of up to 10,250 shares of the company’s common stock to a new employee as an inducement award under the company’s 2019 Inducement Plan.
-
AVROBIO Announces Multiple Clinical Data Presentations, Posters and Events at 17th Annual WORLDSymposium™ 2021
2/1/2021
AVROBIO Announces Multiple Clinical Data Presentations, Posters and Events at 17 th Annual WORLD Symposium ™ 2021 Analyst and investor event scheduled for Monday, Feb. 8 at 8:00 a.m. ET Four platform presentations and two posters on the company’s clinical and preclinical programs for lysosomal disorders are scheduled throughout 17 th annual WORLDSymposium™
-
AVROBIO to Present at the Cowen 2021 Gene Therapy: CMC & Regulatory Summit
1/22/2021
AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Azadeh Golipour, VP of Manufacturing Operations at AVROBIO, will present virtually at the Cowen 2021 Gene Therapy: CMC & Regulatory Summit at 11:30 a.m. ET on Friday, Jan. 29, 2021.
-
BioSpace Movers & Shakers, Jan. 22
1/22/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
AVROBIO to Present at the ICR Conference 2021
1/8/2021
AVROBIO , Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay, president and CEO of AVROBIO, will present virtually at the ICR Conference 2021 at 11:30 a.m. ET on Thursday, Jan. 14, 2021. A live webcast of the presentation can be accessed under "Events and Presentations" in the Investors & Media section
-
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 07, 2021
1/7/2021
AVROBIO, Inc. announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 85,250 shares of the company’s common stock to three new employees as inducement awards under the company’s 2019 Inducement Plan, in accordance with Nasdaq Listing Rule 5635.
-
AVROBIO Announces Grant Under Nasdaq Listing Rule 5635(c)(4)
12/4/2020
AVROBIO , Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to 63,000 shares of the company’s common stock to one new employee as an inducement award under the company’s 2019 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
-
AVROBIO Announces Closing of Underwritten Public Offering
11/24/2020
AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the closing of its previously announced underwritten public offering of 5,000,000 shares of its common stock.
-
AVROBIO Announces Pricing of Underwritten Public Offering of $75 Million of Common Stock
11/20/2020
AVROBIO, Inc., a leading clinical-stage gene therapy company, announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $15.00 per share.
-
AVROBIO Announces Proposed Public Offering of Common Stock - Nov 19, 2020
11/19/2020
AVROBIO, Inc., a leading clinical-stage gene therapy company, announced that it intends to offer and sell, subject to market and other conditions, $75 million of its common stock in an underwritten public offering.
-
AVROBIO Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline
11/17/2020
Three months post-gene therapy, first patient in Gaucher trial shows reductions in the toxic metabolite plasma lyso-Gb1 and plasma chitotriosidase as compared to baseline when the patient was on ERT Ongoing Fabry disease trials continue to demonstrate sustained durability, with first patient out 3.5 years
-
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 06, 2020
11/6/2020
AVROBIO, Inc. announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 52,250 shares of the company’s common stock to four new employees as inducement awards under the company’s 2019 Inducement Plan, in accordance with Nasdaq Listing Rule 5635.
-
AVROBIO Reports Third Quarter 2020 Financial Results and Provides Business Update
11/5/2020
Expanded ex vivo lentiviral gene therapy pipeline with program for Hunter syndrome Received orphan drug designation from the European Commission for two lead programs, AVR-RD-01 for Fabry disease and AVR-RD-02 for Gaucher disease type 1 Clinical and pipeline updates to be shared at Virtual R&D Day on Tuesday, Nov. 17, 2020
-
AVROBIO Receives Orphan Drug Designation from the European Commission for AVR‑RD‑01, an Investigational Gene Therapy for Fabry Disease
10/29/2020
AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the European Commission (EC) has granted orphan drug designation for AVR-RD-01, the company’s investigational gene therapy for the treatment of Fabry disease. AVR-RD-01, an ex-vivo, lentiviral gene therapy, consists of the patient’s own hematopoietic stem ce
-
AVROBIO to Share Clinical and Pipeline Updates at Virtual R&D Day
10/26/2020
AVROBIO, Inc., a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, announced that it will host a Virtual R&D Day for analysts and investors on Nov. 17, 2020, starting at 9:00 a.m. ET.
-
AVROBIO Appoints Dr. Gail Farfel to its Board of Directors
10/21/2020
AVROBIO, Inc., a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, announced the appointment of Gail M. Farfel, Ph.D., to its Board of Directors.